Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer

Overexpression of breast cancer resistance protein (BCRP) has been shown to produce multidrug resistance (MDR) in colon cancer, leading to major obstacles for chemotherapy. In this study, we evaluated the effect of regorafenib, an oral multi-kinase inhibitor, in inhibiting BCRP-mediated MDR in silic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Lett
Main Authors: Zhang, Yun-Kai, Wang, Yi-Jun, Lei, Zi-Ning, Zhang, Guan-Nan, Zhang, Xiao-Yu, Wang, De-shen, Al-Rihani, Sweilem B., Shukla, Suneet, Ambudkar, Suresh V., Kaddoumi, Amal, Shi, Zhi, Chen, Zhe-Sheng
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8148022/
https://ncbi.nlm.nih.gov/pubmed/30392788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2018.10.032
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados